Psyence Biomedical Ltd. Common Shares Total Assets
Psyence Biomedical Ltd. Common Shares total assets. Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) holds total assets worth $12.81 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Psyence Biomedical Ltd. Common Shares for the company's overall valuation and market capitalisation.
Total Assets of Psyence Biomedical Ltd. Common Shares (2021–2025)
Total assets of Psyence Biomedical Ltd. Common Shares from 2021 to 2025. This chart illustrates how Psyence Biomedical Ltd. Common Shares's total assets have evolved over time, based on quarterly financial data. See Psyence Biomedical Ltd. Common Shares (PBM) share price today for real-time trading data and today's change.
Psyence Biomedical Ltd. Common Shares - Asset Composition Analysis
Psyence Biomedical Ltd. Common Shares Total Assets Breakdown (March 2025)
Psyence Biomedical Ltd. Common Shares total assets breakdown as of March 2025. Psyence Biomedical Ltd. Common Shares's total assets of $12.81 Million consist of 89.7% current assets and 10.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.9% |
| Accounts Receivable | $137.35K | 1.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Psyence Biomedical Ltd. Common Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore PBM net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Psyence Biomedical Ltd. Common Shares's current assets represent 89.7% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 83.9% of total assets in 2025, down from 97.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
Psyence Biomedical Ltd. Common Shares Competitors by Total Assets
Key competitors of Psyence Biomedical Ltd. Common Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Psyence Biomedical Ltd. Common Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.09 | 0.64 | 0.05 |
| Quick Ratio | 8.09 | 0.64 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.69 Million | $-1.27 Million | $-227.28K |
Psyence Biomedical Ltd. Common Shares - Advanced Valuation Insights
This section examines the relationship between Psyence Biomedical Ltd. Common Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.26 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | 546.2% |
| Total Assets | $7.32 Million |
| Market Capitalization | $3.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Psyence Biomedical Ltd. Common Shares's assets below their book value (0.43x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Psyence Biomedical Ltd. Common Shares's assets grew by 546.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Psyence Biomedical Ltd. Common Shares (2021–2025)
The table below shows the annual total assets of Psyence Biomedical Ltd. Common Shares from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $7.32 Million | +546.23% |
| 2024-03-31 | $1.13 Million | -99.56% |
| 2023-03-31 | $258.93 Million | +1.06% |
| 2022-03-31 | $256.22 Million | +5127.05% |
| 2021-03-31 | $4.90 Million | -- |
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more